This study describes the importance of mannose-binding lectin (MBL) variant alleles for systemic lupus erythematosus (SLE) 
Introduction
Systemic lupus erythematosus (SLE) is a classical autoimmune disease of unknown origin. 1 It may affect any organ of the body and displays a broad spectrum of clinical and immunological manifestations. There is evidence that hormonal, environmental as well as genetic factors may be implicated in the disease pathogenesis. 2 Although not particularly important in a quantitative sense, deficiencies of components of the classical pathway of complement (C1q, C1r, C1s, C4 or C2) are strongly associated with SLE in a hierarchical manner. 3 It has until recently been the common view that deficiencies in the classical complement pathway leads to SLE because of a defective clearance of immune complexes. 3 However, this notion has been questioned by recent evidence suggesting that the classical pathway components are crucial in handling of cells undergoing programmed cell death (apoptosis). 4 Apoptotic cells are believed to be the main reservoir of autoantigens in SLE.
to SLE by aberrations in the removal mechanism of apoptotic cells thereby inducing breakdown of immunological tolerance and autoimmunization. This hypothesis is favoured by findings in C1q deficient mice, which spontaneously develop an SLE-like syndrome with glomerulonephritis and autoantibody production together with accumulation of apoptotic bodies in the glomeruli. 6 Moreover, complement appears to be crucial for uptake of apoptotic cells by macrophages. 7 Mannose-binding lectin (MBL) is a molecule that shares many features with C1q. 8 In contrast to C1q, which serves as a recognition molecule in the classical pathway, MBL is one of the recognition molecules in the lectin complement activation pathway. 8 Human MBL is derived from a single gene located on chromosome 10 (MBL2). 9, 10 Inter-individual differences in MBL serum concentrations exist because of variant alleles (B, C and D = codons 54, 57 and 52, respectively) in the structural part of the MBL gene. [11] [12] [13] [14] The normal allele is named A and the common designation for the variant alleles is 0. In addition to the association with structural allele variants, the differences in MBL serum levels are determined by polymorphic sites in the promoter region of the MBL2 gene. 15, 16 Particularly, a base substitution in codon −221 (G to C) (promoter allele X) is associated with low MBL serum concentration compared with promoter allele type Y. 15, 16 Deficiency of MBL is associated with increased risk of infections during early childhood, especially in ages between 6 and 18 months 17 and also with severity in patients with a concomitant immunodeficiency or an established infectious disease. [17] [18] [19] [20] [21] [22] In addition several studies have suggested that MBL variant alleles may be weakly associated with SLE. [23] [24] [25] [26] [27] [28] [29] [30] However, no comprehensive analysis of the importance of these alleles for the pathogenesis of SLE exists.
Specific organ involvement is a major determinant for the outcome of SLE, renal and CNS disease in particular. Several surveys have indicated that infections contribute both to morbidity and to mortality in SLE patients. 1, [31] [32] [33] This concept is favoured by our recent finding that deficiency of MBL is associated with a substantially increased risk of complicating infections in a cohort of SLE patients from tertiary referral centres in Copenhagen. 29 In the present study we have asked the questions: (i) do MBL variant alleles confer increased risk of SLE, and (ii) do MBL variant alleles have an influence on the disease progression and/or infection rate in a populationbased cohort? A is the designation for the normal allele. Allele 0 is used as the common designation for the variant alleles B (codon 54), C (codon 57) and D (codon 52). I-SLE indicates incomplete-SLE (Ͻ4 ACR SLE classification criteria). D-SLE indicates definite-SLE (у4 ACR SLE classification criteria). Overall the carrier frequency of 0 genotypes (A/A vs A/0 and 0/0) deviated slightly between the SLE patients and controls (Fisher's P = 0.07, odds ratio: 1.6, 95% CI 0.99-2.5). This difference was confined to patients with D-SLE (Fisher's P = 0.024, odds ratio = 1.8, 95% CI 1.1-3.1), while no difference with patients with I-SLE (Fisher's P Ͼ 0.99, odds ratio = 1.0, 95% CI 0.4-2.3). Neither patients nor controls deviated from the Hardy-Weinberg expectations.
Results
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Genes and Immunity 2.5). This difference was confined to patients with D-SLE (у4 ACR SLE criteria) (Fisher's P = 0.02, odds ratio = 1.8, 95% CI: 1.1-3.1), while no difference between patients and controls was seen with I-SLE (Ͻ4 ACR criteria) (Fisher's P Ͼ 0.99), odds ratio = 1.0, 95% CI: 0.4-2.3). Neither patients nor controls deviated significantly from the Hardy-Weinberg expectations. To estimate the contribution of MBL variant alleles to the development of D-SLE in a population, the population attributable fraction was calculated to be 23.5% according to the formula given by Miettinen. 34 The total frequency of the 0 alleles was 0.29 in patients with D-SLE, 0.18 in I-SLE and 0.20 in controls. MBL downregulating promoter allele X (−221) did not contribute to SLE susceptibility in patients compared with controls (Fisher's P = 0.2) (data not shown). Neither did comparison of those with the lowest MBL serum values (XA/0+0/0 vs YA/0+A/A1) compared with the controls (n = 17 vs n = 82 and n = 40 vs n = 210, respectively Fisher's P = 0.87). Figure 1 shows the downregulating effect of the X allele as well as 0 alleles on the MBL serum concentration.
Analysis of demographic characteristics revealed that the lag time between the first SLE attributable manifestation to a diagnosis of D-SLE was achieved, was shorter for variant allele carriers compared with those with the normal A/A genotype (Table 2 and Figure 2 ) (log rank P = 0.04). By contrast, no association with MBL variant alleles was detected with regard to gender, age at SLE diagnosis and duration of SLE. The frequency of the different SLE classification criteria did not differ between the MBL alleles (Table 3 ). However, during the 2-year follow-up period patients carrying variant alleles had significantly higher erythrocyte sedimentation rate (ESR) (ANOVA, P = 0.04) and SLE disease activity index (SLEDAI-score) (ANOVA, P = 0.02) than those with the A/A genotype ( Figure 3 ).
There was a significant overrepresentation of patients carrying variant alleles who during their medical history (after diagnosis of SLE) had experienced complicating infections, which required admission to hospital (Table  3 ) (Fisher's P = 0.03, odds ratio = 2.8, 95% CI: 1.1-7). Investigation of the time period from diagnosis of SLE to the first infectious event, which required hospitalisation was significantly shorter for variant allele carriers than for the A/A group of patients ( Figure 4 ) (log rank, P = 0.03). Moreover, the annual incidence of complicating infections was about two times higher for variant allele carriers than those with the A/A genotype ( Table 4 ) (P = 0.02). It could be argued that the increased susceptibility for infection in SLE patients due to MBL deficiency could be attributed to the use of cytotoxic drugs (eg, azathioprine or cyclophosphamide), which by itself are highly associated with increased risk of infections in these patients (Fisher's P Ͻ 0.0001 odds ratio = 8.5, 95% CI: 3.0-24.0). Nevertheless, a secondary multiple logistic regression analysis including the use of cytotoxic drugs and MBL alleles as predictive parameters and infections as outcome parameter showed that MBL variant alleles are independent risk factors for infections in these patients (P = 0.006, odds ratio: 4.4 95% CI: 1.5-13.4). However, the MBL effect on infections was stronger in those who had received cytotoxic drugs (n = 42) compared with the patients who had not received cytotoxic drugs (n = 57) because the incidence increased from 3.3% to 20.3% (six-fold) in variant allele carrier while a more moderate increase was seen in the patients with the A/A genotype going from 2.5% to 8.3% (three-fold). Further analysis revealed that the carriers of variant Genes and Immunity alleles were especially susceptible to acquire respiratory infections ( Table 5 ). As can be calculated from Table 6 the risk of acquiring respiratory infections in variant alleles carriers compared with the A/A genotype was increased by a factor 4.6 (95% CI 1.5-13.8, Fisher's P = 0.006).
In order to make a comprehensive analysis of the degree MBL variant alleles might contribute to SLE susceptibility we performed a meta-analysis combining data from studies available on Medline. Only studies, which used у4 ACR SLE criteria to obtain SLE diagnosis were included in the meta-analysis. All studies were hospitalbased and had a case-control design. In the comparisons, we only evaluated presence or absence of structural variant alleles (A/A vs A/0+0/0). No distinction was made between the B, C and D alleles because we assumed that they have a similar downregulating effect on the functional level of MBL. Eight studies reporting SLE association in different ethnic groups were found. [23] [24] [25] [26] [27] [28] [29] [30] The combined analysis revealed that being carrier of an MBL variant allele might increase the risk of developing D-SLE with a factor 1.62 (95% CI: 1.3-2.0, P Ͻ 0.00001). No significant heterogeneity between the studies was observed (P = 0.6) ( Figure 5 ). The population attributable fraction varied from 6% to 32%.
Discussion
Within recent years a number of studies in different ethnic groups have indicated that there is an increased fraction of SLE patients fulfilling four or more of the 1982 ACR criteria (D-SLE) compared with controls who carry MBL variant alleles. [23] [24] [25] [26] [27] [28] [29] [30] The relative risk of having D-SLE for variant allele carriers seems, however, to be rather weak (combined odds ratio 1.62) ranging from 1.2 to 2.8 in the different groups studied. Yet, the population attributable fraction 34 in these studies varied from 6% to 32%, indicating that the variant alleles contribute quite significantly to the overall SLE pathogenesis at a population-based level. This contrasts the other complement deficiency syndromes predisposing to SLE like C1q or C2 deficiency, in which the risk for carriers are extremely high for acquiring SLE, but on a population level the contribution of these syndromes to SLE disease pathogenesis is very low. However, although the above observations are quite uniform the MBL2 gene (10q11.2-q21) has not appeared in genome screenings in sib-pair families as a potential SLE susceptibility locus. 35 The reason for this could be that the necessary sib-pair families to detect small differences has been to low. In analogy several of the studies included in this meta-analysis are insignificant when evaluated individually. Another explanation could be that the MBL2 gene is rather an SLE modifier locus than a true susceptibility locus as discussed below, which may blur sib-pair analyses.
In agreement with the previous observations in tertiary referral centres, [23] [24] [25] [26] [27] [28] [29] [30] we found a significantly increased fraction of D-SLE patients in a population-based cohort carrying variant alleles giving an odds ratio of 1.8 compared with controls and a population attributable risk fraction of 23.5%. This might at first glance lead to the impression that MBL deficiency may predispose to SLE per se. However, our results clearly show that the patients with SLE who did not meet the four ACR criteria at the end of study (I-SLE), had a frequency of MBL variant alleles almost identical to normal controls, 0.18 and 0.20, Poission dispersion test weighted for number of contributing patient years, A/A vs A/0+0/0, chi-square = 5.4, 1 DF P = 0.02. respectively compared with 0.29 in the patients with D-SLE. Moreover, the lag time from first SLE attributable symptom to reach a diagnosis of D-SLE was significantly shorter for variant allele carriers than in those with the A/A genotype, indicating that the MBL2 gene is a disease modifier locus associated with disease severity rather than a true SLE susceptibility locus. In this respect it is interesting that in a recent Japanese SLE study in which no information about whether four or more ACR criteria were met was presented, the frequency of the MBL alleles were the same in patients and controls. 36 The notion that MBL may function as a disease modifier has recently been demonstrated in single genetic disorders as cystic fibrosis, 22 as well as in multifactorial chronic diseases of unknown origin such as rheumatoid arthritis. 37 In the present cohort the variant alleles were not associated with a particular disease entity disclosed by the specific ACR criteria. Nevertheless, in the 2-year followup period, the variant allele carriers had a higher ESR and SLEDAI score than their A/A counterparts indicating that MBL variant alleles predispose to a higher disease activity and, hence, to a poorer long term prognosis.
Previously it has been shown among Chinese patients that genotyping for MBL promoter alleles, which also affect the level of serum MBL may provide additional information. 38 However, this does not seem to be the case in the present Danish patient population. Because our study suggests that the MBL2 gene is a disease modifier locus the contributing effect may be different due to the quantitative contribution from other susceptibility factors (both genetic and environmental) in different populations, which in turn could explain this inconsistency.
In our previous study comprising Danish SLE patients from two major tertiary referral centres we only observed a significant contribution to SLE pathology when the patients were homozygous for MBL variant alleles (0/0). 29 The reason for this difference is not obvious, but might relate to methodological difference in sampling because the SLE patients recruited to the present study comprised all SLE patients from a well-defined geographical area, which is representative for the entire Danish population. Moreover, the former study utilized a retrospective study design based solely on medical records, while in the present study a prospective follow-up period allowing additional information to be generated was included, thereby increasing the reliability of the study.
Although the origin of SLE is unknown, defects in the clearance of apoptotic material and/or immune complexes (waste-disposal hypothesis) by early classical Figure 5 Medline was searched to identify studies investigating whether a primary association may exist between the presence of MBL variant alleles and development of SLE. Only studies enrolling patients fulfilling at least four 1982 ACR criteria (definite-SLE, D-SLE) were included. [23] [24] [25] [26] [27] [28] [29] [30] The combined analysis revealed that being carrier of an MBL variant allele might increase the risk of D-SLE with a factor 1.62 (95% CI: 1.3-2.0, P Ͻ 0.00001). No significant heterogeneity between the studies was observed (P = 0.6). The population attributable fraction varied from 6% to 32%. complement pathway components as well as other opsonins such as C-reactive protein and serum amyloid protein seem to be important mechanisms in the pathophysiology of the disease. 39 Based on the accumulating evidence showing involvement of MBL deficiency in SLE it might be pertinent to speculate that MBL also might be a significant factor in the waste-disposal scenario in SLE.
It is well established that infections play a major role for disease morbidity and mortality in SLE.
1,31-33,40,41 A major outcome in our previous study of Danish SLE patients was the fact that much of the increased risk of infections was related to the presence of MBL variant alleles. 29 This observation has now been confirmed in the present study. The MBL variant alleles conferred a near three-fold increased risk for acquiring infections requiring admission to hospital. Further exploration in these data indicated that the time period from the diagnosis of SLE to the first infectious event was shorter and the annual incidence of infections was higher. A multiple logistic regression analysis including MBL and the use of cytotoxic drugs indicated that the MBL effect was independent of the medication given. Nevertheless, the MBL effect on infections was increased in those patients receiving immunosuppressive drugs. Recently we have shown that in a general healthy population MBL variant alleles seem to predispose to infection only during the so called vulnerable window of infancy from 6 to 18 months of age, while this effect is lost when the adaptive immune system matures. 17 However, several studies have shown increased risk of MBL deficiency for infections beyond this age group. [17] [18] [19] [20] [21] [22] Thus, it is likely that most of these studies actually reflect an aggravating role of MBL in an established disease or a contributing role for MBL, which involves other minor or major immunodeficiencies precipitating immunopathology. It might well be that the increased tendency to infections in SLE is also attributable to multiple immune dysfunctions thereby exposing Genes and Immunity the MBL effect. In our previous study of SLE patients we observed a striking association of MBL deficiency to bacterial pneumonia. 29 This effect is also present in this study, but also other types of respiratory infections seem to be overrepresented in the subset of patients carrying MBL variant alleles in our population-based cohort.
In conclusion, by careful patient sampling in a community-based setting we have shown that the MBL2 gene rather appears to be a disease modifier locus in SLE than a true susceptibility locus. Patients carrying MBL variant alleles have an increased risk of sustained disease activity and a striking tendency to acquire infections. Since MBL substitution therapy has now become available, 42 SLE patients might be candidates for adjunctive MBL therapy.
Patients and methods
Patients were selected from four separate sources from which the epidemiological aspects have been reported previously. 43 The four sources were based on social security numbers from the Central Population Registry. A register covering all in-patients in the period 1 January 1980, to 31 December 1994, was examined. Out-patients could be traced from a parallel register implemented at 1 January 1993. This was searched from that date on to 31 December 1994. Patients with a diagnosis of SLE, discoid lupus, or unspecified connective tissue disease were ascertained from the two registers. Private specialists and general practitioners were asked to report possible new and old cases. Finally, the register of autoimmune tests at the Department of Clinical Immunology, Odense University Hospital was screened for patients testing positive for antinuclear antibodies (ANA) and anti-dsDNA. This register is primarily designed for laboratory use only, encompassing primarily live patients from the County of Funen with positive tests for anti-dsDNA. Patients were included if they were 15 years or older during the study period (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) . Only data relating to the period of residency in the County of Funen were considered. The case records of the patients taken from these sources were reviewed and symptoms, clinical manifestations, and laboratory data were cumulated. All patients suspected of having SLE on these grounds were invited to participate in a structured interview followed by a clinical examination. A total of 890 candidate cases including 318 deceased patients were identified. Among the candidates 127 patients were diagnosed as having SLE in the period 1980 to 1994. Out of these patients 99 were alive in 1995 and eligible for this investigation. Subsequently the patients were followed prospectively for 2 years, which included four visits with interview, clinical examination and laboratory tests to evaluate the present health status. Thus both retrospective and prospective data were obtained. Approval of the investigation was obtained from the local ethics committee.
SLE was diagnosed in accordance with Fries and Holman: evidence of 'multisystem disease, serological positivity, and absence of better diagnosis'. 44 Patients with drug-induced SLE and primary antiphospholipid syndrome were excluded. In addition, the SLE cases were classified according to the 1982 ACR criteria 45 : Those meeting у4 criteria were designated definite (D-SLE), whereas patients meeting Ͻ4 criteria were termed incomplete SLE (I-SLE).
Two-hundred and fifty unrelated healthy Caucasian Danes served as controls (190 blood donors and 60 members of the hospital staff).
Detection of MBL variant alleles
Genomic DNA was isolated from blood cells as described 46 and stored at −20°C. Polymerase chain reaction (PCR) was performed in a volume of 50 l, containing 500 ng genomic DNA, 0.25 M of the specific primers in the presence of 1.5 mM MgCl 2 , 0.2 mM of each dNTP, 50 mM KCl, 10 mM Tris-HCl, pH 8.3, 0.001% (w/v) gelatin and 1 unit AmpliTaq DNA Polymerase (Perkin Elmer, Norwalk, CT, USA). DNA was amplified by general PCR, and by site directed mutagenesis PCR (for details, see Garred et al 14 
)
. All PCRs were initiated by a 2-min denaturation step at 94°C and completed by a 5 min extension step at 72°C. The temperature cycles for the different types of PCRs are as follows: general PCR: 35 cycles of 30 s at 94°C, 60 s at 58°C, 60 s at 72°C. Site directed mutagenesis PCR: 35 cycles of 30 s at 94°C, 30 s at 55°C, 60 s at 72°C.
PCR RFLP
The B and C alleles were detected by Ban I and Mbo II (Amersham, Bucks, UK) restriction enzyme digestion of a 685 base pair PCR product amplified by the MBL exon 1 PCR primers, followed by a 2% agarose gel electrophoresis. The PCR product contains one non-polymorphic Ban I site, which serves as internal control of the enzyme digestion, giving rise to two fragments of 116 bas pair and 569 base pairs. The latter fragment is cleaved into two fragments of 308 base pairs and 261 bp in the A, C, and D genotypes, while it remains uncleaved in the B genotype. The PCR product also contains two nonpolymorphic Mbo II sites, giving rise to three fragments of 83 base pairs, 94 base pairs, and 508 base pairs. The latter fragment was cleaved into two fragments of 280 base pairs and 228 base pairs in the C genotype, while remained uncleaved in the A, B, and D genotypes. The D allele was detected by RFLP performed on SDM-PCR products, which were produced under non-stringent primer annealing condition (55°C), using a mutated 5Ј-primer. The Mlu I restriction enzyme (Amersham) cleaves the 125 base pairs PCR product specific for the D allele into two fragments (100 base pairs and 25 base pairs), while the Hha I restriction enzyme (Amersham) cleaves the A, B, and C alleles. Site directed mutagenesis PCR restriction fragments were separated by 4% Metaphor (FMC, Rockland, ME, USA) agarose gel electrophoresis.
MBL promoter allele typing
Genotyping of promoter alleles was performed by hybridization of sequence-specific oligonucleotide probes to the relevant PCR product.
14 The product was denatured in 0.4 N NaOH and dot blotted onto nylon membranes. Oligonucleotide probes were end-labeled with 32 P-dATP using T4 Polynucleotide kinase. Sequence specific oligonucleotide hybridization was performed at 54°C for 3 h in TMAC 47 solution (50 mM Tris (pH 8), 3 M tetramethylammonium chloride, 2 mM EDTA, 0.1% SDS), × 5 Denhardt's solution and 100 g, heat-denatured herring sperm DNA per ml. This was followed by two 10 min washes at room temperature with × 2 SSPE (180 mM NaCl, 10 mM NaH 2 PO 4 , 1 mM EDTA), 0.1% SDS and two 10 min washes with TMAC solution at 58-61°C, followed by autoradiography.
In this study we compared the effect of the downregulating MBL promoter allele X at codon −221 vs the rest of the alleles Y. 15, 16 In those heterozygous for structural 0 alleles only the promoter on the functional A chromosome was taken into consideration. The X allele is not associated with a haplotype carrying a dysfunctional 0 allele.
14
Quantitation of serum MBL
Serum was kept at −20°C until testing. MBL serum concentrations were measured in a double ELISA as earlier described. 47 The ELISA is based on a monoclonal anti-MBL antibody (clone 131-1, IgG1, kappa) (State Serum Institute, Copenhagen, Denmark). Biotinylated clone 131-1 anti-MBL was used as detector antibody, which is possible because MBL consists of up to 18 identical subunits. The lower detection limit in the assay was 20 g/litre. Because human anti-mouse antibodies or rheumatoid factors may interfere in the assay and give false positive results, parallel plates were run with equivalent amounts of a mouse IgG1, kappa directed against a non-vertebrate protein (limulus). All samples positive on the control plates were tested again with mouse immunoglobulin added to buffer to absorb the unwanted reactivity.
Statistical analyses
Contingency table analyses and Fisher's exact test were used for unpaired comparison of frequencies. Analyses of the lag time from first SLE attributable symptom to the diagnosis of D-SLE was made and the infection-free period were performed with Kaplan-Meier plot and assessed by the log rank test. When appropriate analysis of variance (ANOVA) for repeated measurements were used. Poisson dispersion test weighted for number of contributing patients years was used to test differences in the incidence of infections. To evaluate the depen-dency of MBL on possible confounders we used multiple logistic regression in selected analyses. Because the MBL variant alleles all have a considerable effect on MBL concentrations and in order to avoid small groups, all three variant alleles (B, C, and D) were grouped in one 0 category in the statistical analyses. Two sided tests were used throughout. In addition Medline was searched to identify studies investigating a possible association between the presence of MBL variant alleles and development of SLE. Only studies enrolling patients fulfilling у4 1982 ACR criteria were included. Odds ratios (OR) were estimated by Haldane's modification of Woolf's methods and used to obtain combined estimates (meta-analysis) of OR from the included studies. In addition, this method yields combined chi-square value (with 1 degree of freedom) for deviation from unity (ie no association) and one (with N − 1 degrees of freedom where N is the number of studies combined) for heterogeneity between the OR-values from the individual studies. 48 
